Care From the Comfort of Home: FDA Approves At-Home Starting Dose for Alzheimer’s Treatment

For families navigating the early stages of Alzheimer’s disease, managing treatment can feel like a full-time job. Until recently, receiving advanced anti-amyloid therapy meant scheduling frequent, hours-long appointments at specialized medical facilities. Patients had to travel to a clinic every two weeks just to sit for an intravenous (IV) infusion.

That routine is about to change for the better. On July 13, 2026, the FDA approved a new, once-weekly under-the-skin (subcutaneous) injection version of the Alzheimer's medication Leqembi, branded as Leqembi Iqlik®.

Developed by Eisai and Biogen, this milestone approval means that for the very first time, patients can start their early-stage Alzheimer's treatment right from day one in the comfort of their own homes.

What is Leqembi Iqlik and What Changed?

Leqembi is a targeted antibody therapy designed to clear amyloid plaques—the toxic protein buildups in the brain associated with Alzheimer's disease.

The FDA previously authorized a subcutaneous version of Leqembi back in August 2025, but it came with a significant catch: it was strictly for "maintenance". Patients still had to complete their initial 18 months of treatment via regular IV infusions at a hospital before they could switch to at-home shots.

This new approval completely removes that barrier. Doctors can now prescribe the under-the-skin autoinjector from the very beginning of a patient's treatment journey, giving families full flexibility.

How the At-Home Treatment Works

Instead of enduring an IV line and waiting around an infusion clinic, patients or their caregivers can administer the medication quickly at home using a pre-filled autoinjector.

• The Schedule: The approved starting regimen is a 500 mg dose given once every week.
• The Process: The weekly dose is delivered as two separate 250 mg injections.
• The Time: Each individual injection takes only about 15 seconds to complete.
• Flexibility: Patients can choose to stay on the injection throughout their care or switch back and forth between IV infusions and at-home shots depending on their schedule.

What the Clinical Data Shows

To grant this expanded approval, the FDA reviewed comprehensive data from Phase 3 clinical trials, specifically looking at sub-studies from the Clarity AD long-term extension program. The research confirmed that the weekly at-home injection delivers the exact same medical value as the clinic-based alternative:

• Equal Effectiveness: The weekly under-the-skin injection achieves the same drug exposure levels in the body as the standard IV option, resulting in identical benefits for clearing amyloid plaques and slowing early disease progression.
• Consistent Safety Profile: Rates of key side effects—including amyloid-related imaging abnormalities, or temporary brain swelling/bleeding known as ARIA—were comparable to the IV version.
• Minor Side Effects: Patients using the injection reported a few mild, localized skin reactions at the injection site, but systemic reactions across the rest of the body were rare.
• High Usability: In a specialized device study, 94% of early Alzheimer's patients and their caregivers reported that the autoinjector tool was highly satisfying, confident to use, and easy to operate at home.

Why This is a Major Win for Families

The shift from hospital infusions to at-home injections goes far beyond simple convenience. For patients living in rural areas or dealing with transportation, scheduling, and physical mobility challenges, this approval radically improves access to timely healthcare.

It also drastically lowers the daily burden placed on family caregivers, who no longer need to take frequent time off work to drive their loved ones to medical clinics. Furthermore, by moving these regular treatments out of medical facilities, it frees up critical clinic capacity and infusion chairs for other patients who genuinely require in-office medical supervision.

By turning a complex, hospital-centered procedure into a simple, 15-second weekly routine at home, this approval introduces an incredibly valuable, practical era of care for families managing early Alzheimer's disease.

References & Sources

• Biogen Investor Relations: "FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease" (Published July 13, 2026)
• Alzheimer's Association: "Alzheimer's Association Welcomes Continued Progress in Alzheimer's Treatment with FDA Approval of Leqembi Subcutaneous Starter Dose" (Published July 13, 2026)
• Practical Neurology: "FDA Approves Subcutaneous Leqembi IQLIK as Initiation Dose for Early Alzheimer Disease" (Published July 13, 2026)
• Alzheimer's Drug Discovery Foundation (ADDF): "ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future" (Published July 13, 2026)